Chief Investigators: Malhotra, Novak, Miller, Jenkin. Funding: 2021-23;
Aims: 1. Feasibility of adequate cord blood collection and harvesting of cord blood mononuclear cells in preterm infants born <28 wks' gestation. 2. Safety of autologous intravenous administration at two dosages of cord blood mononuclear cells in the first 2 weeks of life.
Secondary Aims: Neonatal and long term outcomes, including CP.
Mechanism: Anti-inflammatory and trophic.
New Knowledge: First world trial feasibility/safety.
